Journal of Histochemistry and Cytochemistry, Vol. 49, 247-258, February 2001, Copyright © 2001, The Histochemical Society, Inc.


ARTICLE

A Simple Assay and Histochemical Localization of Transglutaminase Activity Using a Derivative of Green Fluorescent Protein as Substrate

Yutaka Furutania, Akira Katoa, Michitaka Notoyaa, Magdy A. Ghoneimb, and Shigehisa Hirosea
a Department of Biological Sciences, Tokyo Institute of Technology, Yokohama, Japan
b Department of Biochemistry, Cairo University, Giza, Egypt

Correspondence to: Shigehisa Hirose, Dept. of Biological Sciences, Tokyo Inst. of Technology, 4259 Nagatsuta-cho, Midoriku, Yokohama 226-8501, Japan. E-mail: shirose@bio.titech.ac.jp


  Summary
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Histidine-tagged green fluorescent protein (His6-Xpress-GFP), a widely used fluorescent probe, was found to be a good substrate for transglutaminase, an enzyme that catalyzes covalent crosslinking of proteins. GFP alone did not serve as a substrate but its derivative His6-Xpress-GFP was readily crosslinked through the Gln and Lys residues present in the short N-terminal extension (His6-Xpress). His6-Xpress-GFP was sensitive enough to detect the transglutaminase activity in guinea pig liver homogenates. The fluorescent substrate could also be used for activity staining of transglutaminase on histological tissue sections, and such applications revealed a surprisingly wide distribution of transglutaminase in the body, especially in the extracellular matrices of various tissues, suggesting an important role for transglutaminase in maintaining the integrity of the extracellular matrix and connective tissues by crosslinking its constituent proteins.

(J Histochem Cytochem 49:247–258, 2001)

Key Words: transglutaminase, green fluorescent protein, extracellular matrix, connective tissue, fluorescent substrate, crosslinking, activity staining, histochemistry


  Introduction
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

TRANSGLUTAMINASES are a family of enzymes that catalyze the transfer of acyl groups between acyl donors and acceptors (Ichinose et al. 1990 ; Greenberg et al. 1991 ; Aeschlimann and Paulsson 1994 ). In this acyl transfer reaction, the Gln side chains of proteins serve as acyl donors and either primary amino groups of several compounds (mostly the Lys side chains of proteins) or hydroxyl groups of T-hydroxyceramides function as acyl acceptor substrates (Nemes et al. 1999 ). The enzymes can therefore form isopeptide crosslinks between the Gln and Lys side chains of proteins or ester bonds between the Gln side chains of proteins and hydroxylipids, and stabilize protein or protein–lipid assemblies; thus the alternative name, crosslinking enzymes. Transglutaminases are widely distributed from bacteria to mammals (Aeschlimann and Paulsson 1994 ; Serafini-Fracassini et al. 1995 ; Mottahedeh and Marsh 1998 ; Chandrashekar and Mehta 2000 ). In mammals, multiple types of transglutaminases have been identified and shown to be strictly dependent on Ca2+, including those in the keratinocyte (TGK, transglutaminase 1; mostly membrane-bound, 106 kD), epidermis (TGE, transglutaminase 3; soluble, 77 kD), prostate (TGP, transglutaminase 4), plasma (blood coagulation factor XIIIa), and epithelial tissues (TGX), and one ubiquitously expressed (TGC, transglutaminase 2). These enzymes are encoded by distinct genes and are heterogeneous in size (~ 80–110 kD) and subunit structure. They undergo a number of different post-translational modifications, such as proteolytic cleavage, phosphorylation, and fatty acylation, regulating their enzymatic activity and subcellular localization (Aeschlimann and Paulsson 1994 ; Esposito et al. 1996 ; Muszbek et al. 1996 ; Steinert et al. 1996 ; Hitomi et al. 1999 ). Acting on particular proteins in the specialized structures mentioned above, they are involved in cornified envelope formation (Hohl 1990 ; Rice et al. 1992 ), cataract formation (Lorand et al. 1981 ; Clement et al. 1998 ), seminal vesicle coagulation (Ho et al. 1992 ), fibrin clot stabilization (Pisano et al. 1968 ), bone formation (Aeschlimann et al. 1996 ), cell growth and differentiation (Birckbichler et al. 1981 ; Kannagi et al. 1982 ; Davies et al. 1988 ; Kojima et al. 1993 ), apoptosis (Dupe et al. 1999 ; Fesus 1998 ; Melino and Piacentini 1998 ), celiac disease (Dieterich et al. 1997 ), maintenance of adherent junctions (Hiiragi et al. 1999 ), and lipid envelope formation (Nemes et al. 1999 ). In addition to the crosslinking reaction, TGC possesses GTPase activity and acts as a novel G-protein (Gh) in {alpha}-adrenergic receptor signaling (Nakaoka et al. 1994 ; Im et al. 1997 ). There is also an inactive member, band 4.2 protein, acting as a structural component of the cytoskeleton (Cohen et al. 1993 ). The above-mentioned multifunctional nature and recent implication in the formation of the senile plaques in Alzheimer's disease (Appelt et al. 1996 ; Yamada et al. 1998 ; Chen and Mehta 1999 ; Kim et al. 1999 ) and the Lewy bodies in Parkinson's disease (Chen and Mehta 1999 ), formation of a chemotactic factor (Nishiura et al. 1999 ), and identification of new types of substrates (Schalkwijk et al. 1999 ) have led to renewed interest in transglutaminases.

We report here a simple method for detection and localization of transglutaminase activities in tissue homogenates and histological sections. The method uses, as a substrate, a derivative of green fluorescent protein (GFP), His6-Xpress-GFP, which can be easily obtained by recombinant DNA technology, and monitors its size changes or covalent anchoring to tissue sections. On histological examination, a surprisingly wide variety of tissues gave strong positive signals, especially in their extracellular matrices, suggesting an important role of transglutaminase in the maintenance of the integrity of the extracellular matrix (ECM).


  Materials and Methods
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Materials
Guinea pigs (male, 8 weeks old) were obtained from Tokyo Laboratory Animal Science (Tokyo, Japan). Guinea pig liver transglutaminase (TGase) and restriction enzymes were purchased from Takara (Kyoto, Japan). pGFPuv vector and rGFPuv were from Clontech (Palo Alto, CA). Ni-NTA agarose resin was from Qiagen, (Chatsworth, CA). pTrcHis A was from Invitrogen (San Diego, CA). Lysyl endopeptidase was from Wako (Tokyo, Japan). µ Bondasphere 5 µ C18-100 Å 3.9 x 150 mm was from Waters (Milford, MA). Tissue-Tek OCT compound was from Miles (Elkhart, IN). Immobilon PSQ membrane was from Millipore (Bedford, MA). 5-(biotinamido)pentylamine was from Pierce (Rockford, IL). Vectabond and horseradish peroxidase–avidin D were from Vector Laboratories (Burlingame, CA). Hydrogenated Triton X-100 and 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt (ABTS) were from Sigma (St Louis, MO). Blood coagulation factor XIIIa (FXIIIa) was a gift from Dr. Yuji Saito (Ueki et al. 1996 ).

Construction of His6-Xpress-GFP Expression Vector
A 0.75-kb PstI-EcoRI fragment of pGFPuv, which encodes the entire open reading frame of GFPuv (abbreviated here simply as GFP), was inserted into the PstI-EcoRI cloning sites of pTrcHis A vector and named pHis6-Xpress-GFP.

Expression and Purification of His6-Xpress-GFP
Escherichia coli JM109 was transformed with pHis6-Xpress-GFP and grown in 2 x Luria Bertani (LB) medium containing 50 µg/ml ampicillin at 37C with aeration until the cells reached an optical density of 0.6 at 600 nm. The expression of His6-Xpress-GFP was induced by addition of 1 mM isopropyl-ß-D-thiogalactopyranoside (IPTG) and incubation was continued at 37C for 5 hr. The cells were harvested by centrifugation at 4000 x g for 20 min and suspended in binding buffer (50 mM phosphate, pH 8.0, containing 500 mM NaCl). The suspensions were treated with lysozyme (1 mg/ml) for 30 min at 4C, and lysed by sonication for 2 min at 4C. The extracts were centrifuged at 10,000 x g for 20 min and supernatant was applied to a column containing 2 ml of Ni-NTA agarose resin. The column was washed with 30 ml of wash buffer (50 mM phosphate, pH 6.0, containing 500 mM NaCl) and wash buffer containing 50 mM imidazole. His6-Xpress-GFP was eluted stepwise with wash buffer containing 100, 200, 350, and 500 mM imidazole, and then dialyzed against 20 mM Tris-HCl, pH 7.5.

Assay by SDS-PAGE of Transglutaminase Activity Using His6-Xpress-GFP as a Substrate
One microgram of tissue transglutaminase was incubated with 0.1 µg of His6-Xpress-GFP or rGFPuv for 1 hr in 20 µl of transglutaminase assay buffer (50 mM Tris-HCl, pH 7.5, 1 mM dithiothreitol, and 5 mM CaCl2) in the presence and absence of 50 mM EDTA or 10 mM putrescine, a transglutaminase inhibitor. The reaction was stopped by adding 5 µl of 5 x Laemlli sample buffer and samples were then separated by SDS-PAGE on a 12.5% gel. After electrophoresis, fluorescent bands in the gel were directly visualized with a Bio-image Analyzer FLA-2000 (Fuji Film; Tokyo, Japan).

Normalization of Activities of Tissue Transglutaminase and FXIIIa and Determination of Their Affinities for His6-Xpress-GFP
For comparison of the affinities of tissue transglutaminase and FXIIIa for the substrate His6-Xpress-GFP, the enzyme levels should be adjusted using a combination of control substrates. This was done by a modified method of Slaughter et al. 1992 using fibrinogen and 5-(biotinamido)pentylamine as substrates. The standard solution of tissue transglutaminase contained 0.31 mg/ml in 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, and 50% glycerol. Wells of 96-well microtiter plates were coated with 100 µl of 20 µg/µl fibrinogen that serves as a substrate (acyl donor) and were stored at room temperature (RT) for 2 hr. The wells were blocked with 0.5% bovine serum albumin (BSA) in Tris-buffered saline (TBS: 10 mM Tris-HCl, pH 7.4, containing 0.15 M NaCl) for 1 hr and washed twice with TBS. Transglutaminase reaction was initiated by adding 5 mM CaCl2, 10 mM dithiothreitol, 0.5 mM 5-(biotinamido)pentylamine, which serves as acyl acceptor, and a dilution series of tissue transglutaminase or FXIIIa. After a 30-min incubation at 37C, the reaction was stopped by 100 mM EDTA. The plate was washed with 0.01% Triton X-100 in TBS, followed by two washes with TBS. The horseradish peroxidase–avidin D was diluted 1:3000 with 0.5% BSA in TBS, added to the wells, and then incubated at RT for 1 hr. The plate was washed once with 0.01% Triton X-100 in TBS, followed by four washes with TBS, and once with C-P buffer (22.75 mM citric acid and 54.5 mM Na2HPO4, pH 5.3), and 100 µl of peroxidase substrate (50 µl of 0.3% H2O2 in MilliQ water and 50 µl of 2 mg/ml ABTS in C-P buffer) was added to each well. Tissue transglutaminase and FXIIIa activities were determined by measuring absorbance at 405 nm (A405). The enzyme activity that catalyzes an increase of A405 = 0.81 for 10 min at 37C was defined as 100 units. On the basis of this normalization, the substrate specificities of the enzymes against His6-Xpress-GFP were determined according to the above-mentioned SDS-PAGE fluorometric method, using the same units of the enzymes.

Isolation, Digestion, and Amino Acid Sequencing of Crosslinked His6-Xpress-GFP
Five hundred pmol of His6-Xpress-GFP and 1 µg of transglutaminase were incubated in 200 µl of transglutaminase assay buffer at 37C for 1 hr. The reaction was stopped by adding 50 µl of 5 x SDS sample buffer. The sample was heat-denatured at 100C for 2 min, electrophoresed in 12.5% SDS-polyacrylamide gels, and then electrotransferred onto an Immobilon-PSQ membrane. After transfer, the membrane was stained with Coomassie Brilliant Blue. The crosslinked band that was seen in the presence of transglutaminase was excised and sequenced either directly for the N-terminal sequence or after digestion with lysyl endopeptidase in 100 mM Tris-HCl, pH 9.5, 10% acetonitrile, and 1% hydrogenated Triton X-100 for C-terminal analysis. The digestion was performed for 24 hr at 37C. Peptide fragments released were purified by reverse-phase HPLC on a Waters C18 column (3.9 x 150 mm) using a 0–60% gradient of acetonitrile in aqueous trifluoroacetic acid (0.8%). Amino acid sequencing was performed with a peptide sequencer (Shimazu PSQ-1100, Kyoto, Japan) using approximately 100 pmol of peptides.

Activity Staining of Transglutaminase in Tissue Sections with His6-Xpress-GFP
Guinea pigs (n = 10) were sacrificed by guillotine or lethal IP injection of sodium pentobarbital. Tissues were immediately removed, frozen in Tissue-Tek OCT compound on dry ice, and stored at -80C. Frozen sections (7 µm) were cut in a cryostat at -16C, mounted on gelatin-coated slides, and air-dried at RT for 30 min. The use of Vectabond for coating slides sometimes gave nonspecific staining (bright dots). Sections were incubated with His6-Xpress-GFP by overlaying 50–200 µl of its solution (0.1 mg/ml) in transglutaminase assay buffer (50 mM Tris-HCl, pH 7.5, 1 mM dithiothreitol, and 5 mM CaCl2) with or without transglutaminase inhibitors (e.g., 50 mM EDTA or 10 mM putrescine) at RT for 1 hr in a moist chamber. The sections were washed three times in excess PBS and covered with coverslips. The samples were analyzed using either a normal fluorescent microscope with mercury lamp and filters for fluorescein isothiocyanate (FITC) fluorescence (Fig 5A–5C) or a laser scanning confocal microscope (TCS4D, Leica Laser Teknik) based on a Zeiss Axiovert microscope (Carl Zeiss; Oberkochen, Germany) interfaced with a mixed gas argon–krypton laser. Fluorescence acquisitions were performed with the 488-nm laser line to excite GFP (Fig 5D–5U). The fluorescence was very stable. The stained specimens could be viewed repeatedly for at least 3 weeks if stored in a humidified chamber at 4C.



View larger version (59K):
[in this window]
[in a new window]
 
Figure 1. Nucleotide and amino acid sequences of His6-Xpress-GFP. The nucleotide sequence derived from the pTrcHis vector is denoted by capital letters and that from pGFPuv is indicated by lower-case letters. The pTrcHis vector encodes the N-terminal extension: histidine (His) tag and Xpress sequence. Gray boxes indicate partial N-terminal sequences contained in the N-terminal and C-terminal fragments generated from His6-Xpress-GFP after its incubation with transglutaminase (Fig 2, Lane 3; lower band of 36 kD) and digestion with lysyl endopeptidase. Glutamine residues (Q) in the N-terminal extension (Xpress) that can serve as acyl donors are boxed and lysine residues (K) that can act as acyl acceptors are indicated by white on black background.



View larger version (44K):
[in this window]
[in a new window]
 
Figure 2. Detection of transglutaminase activity using a fluorescent substrate, His6-Xpress-GFP. (A) SDS-PAGE analysis of GFP and its derivative, His6-Xpress-GFP, treated with transglutaminase. Recombinant GFP (rGFPuv) and its derivative His6-Xpress-GFP (0.5 µg each) were incubated with purified transglutaminase (TGase, 0.15 µg) in the presence and absence of EDTA, a transglutaminase inhibitor, at 37C for 60 min and were separated on 12.5% SDS-PAGE gel. The gel was scanned with a Bio-imaging system FLA-2000 using excitation at 473 nm and emission at >520 nm. As expected, His6-Xpress-GFP gave a slightly higher molecular mass (41 kD, Lane 4) than GFP (38 kD, Lane 2), reflecting its N-terminal extension. In Lane 5, 2 µg of His6-Xpress-GFP was used. (B) Crosslinking of His6-Xpress-GFP by transglutaminase in the liver. His6-Xpress-GFP was incubated with guinea pig liver homogenates and analyzed by SDS-PAGE. The gel was scanned using FLA-2000 (Lanes 6 and 7) and then stained with Coomassie Brilliant Blue (CBB; Lanes 8 and 9). In Lanes 7 and 9, EDTA was added to inactivate transglutaminase. In Lane 6, intra- and intermolecularly crosslinked species are seen as fluorescent bands including those at 36, 55, and 120 kD and those at the top of the gel. (C) Electrophoretic mobility shift of His6-Xpress-GFP on heat denaturation. When His6-Xpress-GFP was boiled in the presence of SDS, its apparent molecular mass was changed from 41 kD to 34 kD, a value close to the calculated one (33 kD). The 41-kD fluorescent form is expected to maintain the folded structure that binds less SDS and runs more slowly on SDS-PAGE compared to the fully elongated 34-kD nonfluorescent form.



View larger version (33K):
[in this window]
[in a new window]
 
Figure 3. Time course of crosslinking of His6-Xpress-GFP by transglutaminase. (A) SDS-PAGE analysis of reaction products. His6-Xpress-GFP and purified transglutaminase were incubated at 37C for the indicated period of time. The reaction was stopped with EDTA. Reaction products were separated by 12.5% SDS-PAGE gel (A) and quantified with a fluorescence scanner FLA-2000 (B). (B) Quantitative representation of A. Open circles represent fluorescence intensities of the 36-kD crosslinked product and closed circles those of non-crosslinked substrate (41-kD band). H6-Xpr-GFP, His6-Xpress-GFP.



View larger version (16K):
[in this window]
[in a new window]
 
Figure 4. Lower affinity of His6-Xpress-GFP to FXIIIa than to tissue transglutaminase. Variable amounts of purified preparations of FXIIIa (closed circles) and liver transglutaminase (tissue TGase; open circles), whose relative activities were adjusted using 5-(biotinamido)pentylamine as a standard substrate, were incubated with a constant amount of His6-Xpress-GFP at 37C for 1 hr and the reaction products were analyzed as in Fig 3.






View larger version (402K):
[in this window]
[in a new window]
 
Figure 5. Locations of transglutaminase visualized by activity staining of guinea pig tissue sections. Fresh tissues were frozen, sectioned in a cryostat, and stained with His6-Xpress-GFP (A–S) or hematoxylin (A'–C'). Tissues examined are: (A), esophagus; (B), thin skin; (C), liver; (D), lung; (E), testis; (F), pituitary gland; (G),aorta; (H),spleen; (I), spleen + EDTA; (J), large intestine; (K), kidney; (L), seminal vesicle; (M), urinary bladder; (N), small intestine; (O), thyroid; (P), tongue; (Q), tongue + EDTA; (R), thin skin; (S), thin skin + putrescine; (T), heart; and (U), serial section of T (heart) stained after extensive washing with PBS. A, alveolus; B, bronchiole; BV, blood vessel; Ca, capsule; CT, connective tissue; CV, central vein; D, dermis; E, epidermis; En, endomysium; Ep, epithelium; F, follicle; FL, fibroreticular lamina; IC, inner circular muscle; IL, inferior longitudinal muscle; L, lumen; LF, luminal fluid; LP, lamina propria; ME, muscularis externa; MF, mucosa fold; MM, muscularis mucosae; OL, outer longitudinal muscle; PD, pars distalis; PI, pars intermedia; PN, pars nervosa; RC, renal corpuscle; SC, stratum corneum; SE, seminiferous epithelium; SG, stratum glanulosum; SL, superior longitudinal; Sm, submucosa; SM, smooth muscle; ST, seminiferous tubules; T, tubule; TA, tunica adventitia; TI, tunica intima; TM, tunica media. Bars: A–G,J–N,P,Q = 100 µm; H,I,O,R–U = 50 µm.


  Results
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Construction and Purification of GFP Derivatives
The E. coli expression vector pTrcHis used in this study is designed for high-level expression of His-tagged recombinant proteins. The proteins produced have a polyhistidine (6 x His) tag on the N-terminus for rapid purification, which is followed by the Xpress epitope and the enterokinase cleavage site for removal of the fused tags. We noted the presence of two Gln and one Lys in the short stretch of the Xpress epitope and enterokinase cleavage site (Fig 1) and considered the possibility that if GFP is produced as a His6-Xpress-GFP fusion protein using the pTrcHis vector, it may serve as a useful fluorescent substrate of transglutaminase. We therefore produced the His6-Xpress-GFP fusion protein in E. coli and purified it by Ni-chelate chromatography as described in Materials and Methods. The yield was about 3 mg per liter of bacterial culture. The purified protein gave a single fluorescent band of 41 kD on SDS-PAGE (Fig 2, Lanes 4 and 10). Like the wild-type GFP, the N-terminally extended GFP was resistant to the reducing agent 2-mercaptoethanol but sensitive to heat denaturation in the presence of SDS (Fig 2, lane 11). The heat-denatured nonfluorescent His6-Xpress-GFP migrated as a band of 34 kD, a value close to the calculated molecular weight (32,776).

Electrophoretic Mobility Shift of Crosslinked GFP Derivatives
When His6-Xpress-GFP was incubated with transglutaminase and analyzed by SDS-PAGE, significant changes were observed in its electrophoretic mobility (Fig 2, Lane 3). The wild-type GFP showed no such changes (Fig 2, Lane 1). EDTA, an inhibitor of transglutaminase, completely inhibited the mobility changes (Fig 2, Lane 4). Similar inhibitory effects were also seen with putrescine, a competitive inhibitor of transglutaminase (data not shown). Depending on the incubation time, the transglutaminase-treated His6-Xpress-GFP behaved as compact molecules at the initial stage (Fig 2, Lane 3, lower band of 36 kD) and as much larger molecules at later stages of the treatment or at higher concentrations of the substrate (Fig 2, Lane 5). Fig 3 shows the time course of the crosslinking reaction monitored by measuring the fluorescence intensity of the 36-kD band (open circle). It appears unlikely that the lower molecular weight species are proteolytic degradation products because (a) the transglutaminase used is a highly purified preparation, (b) the N-terminal amino acid sequence of the lower molecular weight species (RGSHHHHHH; Fig 1, shading) matched perfectly to that of His6-Xpress-GFP, and (c) amino acid sequencing of lysyl endopeptidase-generated peptide fragments of the lower molecular weight species revealed the presence of the C-terminal fragment beginning with the sequence RDHMVLLEFVTA (Fig 1, shading). The initial lowering of the apparent molecular size (from 41 kD to 36 kD) and the later appearance of the higher molecular weight species (>50 kD) may therefore be due to intramolecular and intermolecular crosslinking, respectively, of His6-Xpress-GFP by transglutaminase.

Higher Affinity for Tissue Transglutaminase
There are several types of transglutaminase that are encoded by separate genes, including keratinocyte transglutaminase, plasma transglutaminase (blood coagulation factor XIIIa, FXIIIa), tissue transglutaminase, and prostate gland transglutaminase. Among these, plasma and tissue transglutaminases are widely distributed in the body. We therefore determined whether the fluorescent substrate His6-Xpress-GFP serves as a substrate for plasma transglutaminase as well as for tissue transglutaminase by first activating the purified preparation of plasma transglutaminase with thrombin and then mixing it with the substrate. His6-Xpress-GFP turned out to be a very poor substrate for plasma transglutaminase (Fig 4). When both enzyme activities were adjusted to the same level by using the synthetic substrate 5-(biotinamido)pentylamine and their crosslinking abilities toward His6-Xpress-GFP were compared, plasma transglutaminase exhibited only weak activity. This weak activity of plasma transglutaminase toward His6-Xpress-GFP is consistent with its narrow substrate specificity; it is highly specific for fibrin.

Detection of Transglutaminase Activity in Tissue Extracts
To evaluate the usefulness of His6-Xpress-GFP as a transglutaminase substrate, we prepared guinea pig liver homogenate, incubated it with His6-Xpress-GFP, and analyzed the reaction products by SDS-PAGE (Fig 2B). Incubation of the fluorescent substrate with the liver homogenate resulted in its intra- and inter-molecular crosslinking (Fig 2, Lanes 6 and 8), indicating that His6-Xpress-GFP is sensitive enough to detect the transglutaminase activity in tissue extracts.

Detection of Transglutaminase Activity on Tissue Sections
Fig 5 shows that His6-Xpress-GFP can also be used for histological purposes, i.e., activity staining of transglutaminase on tissue sections. When incubated with non-fixed frozen sections of a variety of guinea pig tissues shown in Fig 5, His6-Xpress-GFP was crosslinked to certain discrete structures, such as the stratified squamous epithelium of the skin, smooth muscle layers of the blood vessels and ducts, and connective tissues, giving a clear fluorescent pattern of the localization of active transglutaminase. In general, transglutaminase activities appear to be relatively concentrated in the ECM of various tissues.

In the esophagus, very bright fluorescent staining was seen in the endomysium of the muscularis mucosae (Fig 5A). In the skin, fluorescent labeling was seen in the upper spinous and granular layers of epidermis (Fig 5B and Fig 5R), where membrane-bound keratinocyte transglutaminase has been demonstrated by immunohistochemistry (Michel and Demarchez 1988 ). In the liver, blood vessels and bile ducts were strongly decorated with His6-Xpress-GFP; the reticular network around sinusoids was also weakly stained (Fig 5C). In the lung, blood vessels, bronchioles, and connective tissue elements of alveoli were stained (Fig 5D), in the testis, the fibroreticular lamina (Fig 5E), and in the pituitary, connective tissues, especially thin layers of connective tissues surrounding endocrine cells in the pars distalis (Fig 5F). In the aorta, elastic lamellae of the tunica media (Fig 5G) were stained, in the spleen, reticular scaffolding of the sinuses (Fig 5H), and in the large intestine, muscularis mucosae and subserosal connective tissues and endomysium of muscularis externa (Fig 5J). In the kidney, connective tissues of the tubules (Fig 5K) were stained, in the seminal vesicle, connective tissues of smooth muscle and mucosa fold (Fig 5L), and in the urinary bladder, endomysium of the smooth muscle (Fig 5M). In the small intestine, dense connective tissues of submucosa, connective tissues of lamina propria and serosa, and endomysium of muscularis externa (Fig 5N) were stained, in the thyroid, connective tissues surrounding the folicular cells (Fig 5O), in the tongue, blood vessels and endomysium of the inferior longitudinal muscle (Fig 5P), and in the heart, endomysium (Fig 5T). These labelings were not present on the control sections processed in parallel in the presence of EDTA (e.g., Fig 5I and Fig 5Q) or putrescine (e.g., Fig 5S). The degree of cellular labeling was greatly reduced when tissue sections were washed extensively with PBS before incubation with His6-Xpress-GFP, whereas the labeling of ECM and connective tissues remained relatively unaltered. As a typical example, the staining patterns of heart sections with and without washing are shown in Fig 5T and Fig 5U. This result suggests that the weak cellular labeling is mainly due to the soluble tissue transglutaminase (transglutaminase 2 or TGC) and that the enzyme responsible for the relatively strong labeling of ECM is tightly associated with their components.


  Discussion
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Two types of histological methods have been used for determining cellular localization of transglutaminase: immunohistochemistry and activity staining. In the previous activity staining method, active transglutaminases are detected on tissue sections by incubation with monodansylcadaverine (Aeschlimann and Paulsson 1991 ) or 5-(biotinamido)pentylamine (Perry et al. 1995 ) and then by visualizing the incorporated monodansylcadaverine or 5-(biotinamido)pentylamine with anti-dansyl antibody or FITC-labeled avidin. The in situ transglutaminase assay reported here is relatively highly sensitive and therefore does not require amplification with anti-GFP antiserum, making the procedure simple and reliable. Another advantage is that His6-Xpress-GFP has both reactive Gln and Lys residues that serve as an acyl donor and an acceptor, respectively, whereas monodansylcadaverine and 5-(biotinamido) pentylamine can serve only as acyl acceptors. The GFP fluorescence was very stable compared to that of FITC, and practically no fading occurred during observation with a normal fluorescence microscope equipped with FITC optics. Helped by this sensitivity, stability, and simplicity, we could perform a large number of activity stainings of transglutaminase in a series of guinea pig tissues and found a surprisingly wide distribution of the crosslinking enzyme, especially in the ECM. This result demonstrates the previously unrecognized importance of transglutaminase in maintaining the integrity of ECM as well as the well-established roles in maintaining the barrier function of the skin (Hohl 1990 ; Matsuki et al. 1998 ; Ishida-Yamamoto and Iizuka 1998 ; Nemes and Steinert 1999 ) and in stabilizing fibrin clots (Muszbek et al. 1996 ; Mosesson 1998 ). The strong staining of the extracellular matrix mentioned above was somewhat unexpected because (a) tissue transglutaminase lacks the presequence, (b) keratinocyte transglutaminase is membrane-bound (Rice et al. 1992 ), and (c) the extracellular transglutaminase FXIIIa has very weak affinity for the fluorescent substrate His6-Xpress-GFP. But the result is consistent with the accumulating evidence that, although the mechanism is unknown, a high proportion of transglutaminase is secreted into the extracellular space and remains there (Aeschlimann et al. 1993 ; Nurminskaya et al. 1998 ; Gaudry et al. 1999 ). Identification by Dieterich et al. 1997 of tissue transglutaminase as the endomysial autoantigen recognized by serum samples of patients with celiac disease is also consistent with our staining results. Celiac disease is characterized by small intestinal damage caused by autoantibodies against components of the fibroreticular scaffolding and endomysium, a structure of the smooth muscle connective tissue. The work of Dieterich et al. 1997 therefore strongly suggests that transglutaminase is one of the components of the endomysium.

Our original intention to devise an in situ transglutaminase assay was to demonstrate the presence of active transglutaminase in the brain and in the nucleus of the cell, the locations currently receiving considerable attention in relation to transglutaminase and neuronal development (Hand et al. 1993 ) and neurodegenerative disorders (Lorand 1996 ; Igarashi et al. 1998 ; Kahlem et al. 1998 ; Chen and Mehta 1999 ) and regulation of nuclear functions (Shimizu et al. 1996 ; Lesort et al. 1998 ; Peng et al. 1999 ). However, we could not detect significant levels of the activity in these structures, probably because of very low levels of transglutaminase and insufficient sensitivity of the assay for covering such low levels. Alternatively, in these structures the expression of transglutaminase activity may be induced under certain abnormal conditions, such as diseases and apoptosis. In the present study, we demonstrated the usefulness of a GFP derivative, His6-Xpress-GFP, for visualizing active transglutaminase on normal histochemical sections. It would also be useful for determining locations and levels of transglutaminases in clinical specimens. Another potential use of His6-Xpress-GFP would be for preparing GFP-labeled proteins which, in turn, can be used as fluorescent histochemical probes. For example, many antibodies, lectins, and protein ligands are expected to be able to be labeled with His6-Xpress-GFP in the presence of transglutaminase through their Gln and Lys side chains.


  Acknowledgments

Supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sport and Culture of Japan, by a Research Grant for Cardiovascular Diseases (11C-1) from the Ministry of Health and Welfare of Japan, and by an SRF Grant for Biomedical Research. YF is supported by a Research Fellowship for Young Scientists from the Japan Society for the Promotion of Science.

We thank Dr Yuji Saito and Hiroo Takahashi for discussion and help in the FXIIIa assay, and Setsuko Satoh for secretarial assistance.

Received for publication April 7, 2000; accepted August 23, 2000.


  Literature Cited
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Aeschlimann D, Mosher D, Paulsson M (1996) Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Semin Thromb Hemost 22:437-443[Medline]

Aeschlimann D, Paulsson M (1991) Crosslinking of laminin-nidogen complexes by tissue transglutaminase. A novel mechanism for basement membrane stabilization. J Biol Chem 266:15308-15317[Abstract/Free Full Text]

Aeschlimann D, Paulsson M (1994) Transglutaminases: protein crosslinking enzymes in tissues and body fluids. Thromb Haemost 71:402-415[Medline]

Aeschlimann D, Wetterwald A, Fleisch H, Paulsson M (1993) Expression of tissue transglutaminase in skeletal tissues correlates with events of terminal differentiation of chondrocytes. J Cell Biol 120:1461-1470[Abstract]

Appelt DM, Kopen GC, Boyne LJ, Balin BJ (1996) Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease. J Histochem Cytochem 44:1421-1427[Abstract]

Birckbichler PJ, Orr GR, Patterson MK, Jr, Conway E, Carter HA (1981) Increase in proliferative markers after inhibition of transglutaminase. Proc Natl Acad Sci USA 78:5005-5008[Abstract]

Chandrashekar R, Mehta K (2000) Transglutaminase-catalyzed reactions in the growth, maturation and development of parasitic nematodes. Parasitol Today 16:11-17[Medline]

Chen JS, Mehta K (1999) Tissue transglutaminase: an enzyme with a split personality. Int J Biochem Cell Biol 31:817-836[Medline]

Clement S, Velasco PT, Murthy SN, Wilson JH, Lukas TJ, Goldman RD, Lorand L (1998) The intermediate filament protein, vimentin, in the lens is a target for crosslinking by transglutaminase. J Biol Chem 273:7604-7609[Abstract/Free Full Text]

Cohen CM, Dotimas E, Korsgren C (1993) Human erythrocyte membrane protein band 4.2 (pallidin). Semin Hematol 30:119-137[Medline]

Davies PJ, Basilion JP, Chiocca EA, Johnson J, Poddar S, Stein JP (1988) Retinoids as generalized regulators of cellular growth and differentiation. Am J Med Sci 296:164-170[Medline]

Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nature Med 3:797-801[Medline]

Dupe V, Ghyselinck NB, Thomazy V, Nagy L, Davies PJA, Chambon P, Mark M (1999) Essential roles of retinoic acid signaling in interdigital apoptosis and control of BMP-7 expression in mouse autopods. Dev Biol 208:30-43[Medline]

Esposito C, Pucci P, Amoresano A, Marino G, Cozzolino A, Porta R (1996) Transglutaminase from rat coagulating gland secretion. Post-translational modifications and activation by phosphatidic acids. J Biol Chem 271:27416-27423[Abstract/Free Full Text]

Fesus L (1998) Transglutaminase-catalyzed protein crosslinking in the molecular program of apoptosis and its relationship to neuronal processes. Cell Mol Neurobiol 18:683-694[Medline]

Gaudry CA, Verderio E, Jones RA, Smith C, Griffin M (1999) Tissue transglutaminase is an important player at the surface of human endothelial cells: evidence for its externalization and its colocalization with the ß1 integrin. Exp Cell Res 252:104-113[Medline]

Greenberg CS, Birckbichler PJ, Rice RH (1991) Transglutaminases: multifunctional crosslinking enzymes that stabilize tissues. FASEB J 5:3071-3077[Abstract/Free Full Text]

Hand D, Perry MJ, Haynes LW (1993) Cellular transglutaminases in neural development. Int J Dev Neurosci 11:709-720[Medline]

Hiiragi T, Sasaki H, Nagafuchi A, Sabe H, Shen SC, Matsuki M, Yamanishi K, Tsukita S (1999) Transglutaminase type 1 and its crosslinking activity are concentrated at adherens junctions in simple epithelial cells. J Biol Chem 274:34148-34154[Abstract/Free Full Text]

Hitomi K, Kanehiro S, Ikura K, Maki M (1999) Characterization of recombinant mouse epidermal-type transglutaminase (TGase 3): regulation of its activity by proteolysis and guanine nucleotides. J Biochem (Tokyo) 125:1048-1054[Abstract]

Ho KC, Quarmby VE, French FS, Wilson EM (1992) Molecular cloning of rat prostate transglutaminase complementary DNA. The major androgen-regulated protein DP1 of rat dorsal prostate and coagulating gland. J Biol Chem 267:12660-12667[Abstract/Free Full Text]

Hohl D (1990) Cornified cell envelope. Dermatologica 180:201-211[Medline]

Ichinose A, Bottenus RE, Davie EW (1990) Structure of transglutaminases. J Biol Chem 265:13411-13414[Free Full Text]

Igarashi S, Koide R, Shimohata T, Yamada M, Hayashi Y, Takano H, Date H, Oyake M, Sato T, Sato A, Egawa S, Ikeuchi T, Tanaka H, Nakano R, Tanaka K, Hozumi I, Inuzuka T, Takahashi H, Tsuji S (1998) Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nature Genet 18:111-117[Medline]

Im MJ, Russell MA, Feng JF (1997) Transglutaminase II: a new class of GTP-binding protein with new biological functions. Cell Signal 9:477-482[Medline]

Ishida–Yamamoto A, Iizuka H (1998) Structural organization of cornified cell envelopes and alterations in inherited skin disorders. Exp Dermatol 7:1-10[Medline]

Kahlem P, Green H, Djian P (1998) Transglutaminase action imitates Huntington's disease: selective polymerization of huntingtin containing expanded polyglutamine. Mol Cell 1:595-601[Medline]

Kannagi R, Teshigawara K, Noro N, Masuda T (1982) Transglutaminase activity during the differentiation of macrophages. Biochem Biophys Res Commun 105:164-171[Medline]

Kim SY, Grant P, Lee JH, Pant HC, Steinert PM (1999) Differential expression of multiple transglutaminases in human brain. Increased expression and crosslinking by transglutaminases 1 and 2 in Alzheimer's disease. J Biol Chem 274:30715-30721[Abstract/Free Full Text]

Kojima S, Nara K, Rifkin DB (1993) Requirement for transglutaminase in the activation of latent transforming growth factor-ß in bovine endothelial cells. J Cell Biol 121:439-448[Abstract]

Lesort M, Attanavanich K, Zhang J, Johnson GV (1998) Distinct nuclear localization and activity of tissue transglutaminase. J Biol Chem 273:11991-11994[Abstract/Free Full Text]

Lorand L (1996) Neurodegenerative diseases and transglutaminase. Proc Natl Acad Sci USA 93:14310-14313[Free Full Text]

Lorand L, Hsu LK, Siefring GE, Jr, Rafferty NS (1981) Lens transglutaminase and cataract formation. Proc Natl Acad Sci USA 78:1356-1360[Abstract]

Matsuki M, Yamashita F, Ishida–Yamamoto A, Yamada K, Kinoshita C, Fushiki S, Ueda E, Morishima Y, Tabata K, Yasuno H, Hashida M, Iizuka H, Ikawa M, Okabe M, Kondoh G, Kinoshita T, Takeda J, Yamanishi K (1998) Defective stratum corneum and early neonatal death in mice lacking the gene for transglutaminase 1 (keratinocyte transglutaminase). Proc Natl Acad Sci USA 95:1044-1049[Abstract/Free Full Text]

Melino G, Piacentini M (1998) ‘Tissue’ transglutaminase in cell death: a downstream or a multifunctional upstream effector? FEBS Lett 430:59-63[Medline]

Michel S, Demarchez M (1988) Localization and in vivo activity of epidermal transglutaminase. J Invest Dermatol 90:472-474[Abstract]

Mosesson MW (1998) Fibrinogen structure and fibrin clot assembly. Semin Thromb Hemost 24:169-174[Medline]

Mottahedeh J, Marsh R (1998) Characterization of 101-kD transglutaminase from Physarum polycephalum and identification of LAV1-2 as substrate. J Biol Chem 273:29888-29895[Abstract/Free Full Text]

Muszbek L, Adany R, Mikkola H (1996) Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 33:357-421[Medline]

Nakaoka H, Perez DM, Baek KJ, Das T, Husain A, Misono K, Im MJ, Graham RM (1994) Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science 264:1593-1596[Medline]

Nemes Z, Marekov LN, Fesus L, Steinert PM (1999) A novel function for transglutaminase 1: attachment of long-chain {omega}-hydroxyceramides to involucrin by ester bond formation. Proc Natl Acad Sci USA 96:8402-8407[Abstract/Free Full Text]

Nemes Z, Steinert PM (1999) Bricks and mortar of the epidermal barrier. Exp Mol Med 31:5-19[Medline]

Nishiura H, Tanase S, Sibuya Y, Nishimura T, Yamamoto T (1999) Determination of the crosslinked residues in homo-dimerization of S19 ribosomal protein concomitant with exhibition of monocyte chemotactic activity. Lab Invest 79:915-923[Medline]

Nurminskaya M, Magee C, Nurminsky D, Linsenmayer TF (1998) Plasma transglutaminase in hypertrophic chondrocytes: expression and cell-specific intracellular activation produce cell death and externalization. J Cell Biol 142:1135-1144[Abstract/Free Full Text]

Peng X, Zhang Y, Zhang H, Graner S, Williams JF, Levitt ML, Lokshin A (1999) Interaction of tissue transglutaminase with nuclear transport protein importin-{alpha}3. FEBS Lett 446:35-39[Medline]

Perry MJ, Mahoney SA, Haynes LW (1995) Transglutaminase C in cerebellar granule neurons: regulation and localization of substrate crosslinking. Neuroscience 65:1063-1076[Medline]

Pisano JJ, Finlayson JS, Peyton MP (1968) Crosslink in fibrin polymerized by factor 13: epsilon-(gamma-glutamyl)lysine. Science 160:892-893[Medline]

Rice RH, Mehrpouyan M, O'Callahan W, Parenteau NL, Rubin AL (1992) Keratinocyte transglutaminase: differentiation marker and member of an extended family. Epithel Cell Biol 1:128-137[Medline]

Schalkwijk J, Wiedow O, Hirose S (1999) The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J 340:569-577[Medline]

Serafini–Fracassini D, Del Duca S, Beninati S (1995) Plant transglutaminases. Phytochemistry 40:355-365[Medline]

Shimizu T, Hozumi K, Horiike S, Nunomura K, Ikegami S, Takao T, Shimonishi Y (1996) A covalently crosslinked histone. Nature 380:32[Medline]

Slaughter TF, Achyuthan KE, Lai TS, Greenberg CS (1992) A microtiter plate transglutaminase assay utilizing 5-(biotinamido)pentylamine as substrate. Anal Biochem 205:166-171[Medline]

Steinert PM, Kim SY, Chung SI, Marekov LN (1996) The transglutaminase 1 enzyme is variably acylated by myristate and palmitate during differentiation in epidermal keratinocytes. J Biol Chem 271:26242-26250[Abstract/Free Full Text]

Ueki S, Takagi J, Saito Y (1996) Dual functions of transglutaminase in novel cell adhesion. J Cell Sci 109:2727-2735[Abstract/Free Full Text]

Yamada T, Yoshiyama Y, Kawaguchi N, Ichinose A, Iwaki T, Hirose S, Jefferies WA (1998) Possible roles of transglutaminases in Alzheimer's disease. Dement Geriatr Cogn Disord 9:103-110[Medline]